For life sciences companies, the rules for conducting day-to-day international operations and transaction tax planning have changed dramatically as a result of recent U.S. tax reform as well as certain global tax developments. Whether it relates to intangible or fixed assets, intellectual property, where and how to best manage cash and reinvestments, acquiring international targets, or establishing operations abroad, U.S. tax reform presents a multitude of new issues for life sciences companies to consider. During this webinar, we’ll explore how these issues are impacting transaction, compliance, and provision planning for these companies. We will also touch on how the new regulations and guidance have raised more questions and reporting complexities.